Table 1.
Baseline characteristics of the subjects in the full analysis set
| Famotidine group, n = 23 | Placebo group, n = 24 | p value | |
|---|---|---|---|
| Gender male:female, n | 4:19 | 4:20 | ns |
| Age, years, mean ± SD | 45.0±15.0 | 47.8±13.8 | ns |
| Body mass index, kg/m2, mean ± SD | 22.7±4.7 | 19.1±2.3 | 0.007 |
| Helicobacter pylori, n | ns | ||
| Negative | 21 | 16 | |
| Negative after eradication | 2 | 4 | |
| Positive | 0 | 4 | |
| Chief bothersome symptoms, n | ns | ||
| EPS-related symptoms | 9 | 8 | |
| PDS-related symptoms | 7 | 13 | |
| EPS- and PDS-related symptoms | 7 | 3 | |
| Disease period, n | ns | ||
| Unknown | 2 | 3 | |
| <1 month | 0 | 0 | |
| 1≤, <3 months | 3 | 4 | |
| 3≤, <6 months | 1 | 1 | |
| 6≤, <12 months | 2 | 4 | |
| ≤12 months | 15 | 12 | |
| Total abdominal symptom scores, mean ± SD | 9.7±4.25 | 8.4±4.33 | ns |
ns, not significant.